Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.63 |
| ▸ | GLP1R | P43220 | 4/20 | 0.62 |
| ▸ | GCGR | P47871 | 3/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | NMBR | P28336 | 2/20 | 0.59 |
| ▸ | GRPR | P30550 | 2/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.57 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | MC5R | P33032 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25665234 | 0.94 | CTSL (0.69) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL26426177 | 0.93 | CTSL (0.64) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL25664282 | 0.93 | CTSL (0.66) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL25664250 | 0.92 | CTSL (0.65) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL25665363 | 0.91 | CTSL (0.69) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL25664212 | 0.91 | CTSL (0.68) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL26428433 | 0.90 | CTSL (0.65) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL25664225 | 0.89 | CTSL (0.67) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL26426063 | 0.89 | CTSL (0.64) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30439204 | 0.88 | C5AR1 (0.66) | CTSLCTSSCTSKCTSHGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | CTSL 56/4885CTSS 369/4885CTSK 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.